- World rank, 2022–2025
- #19,932 of 28,054 · #25,114 all time
- Rank in Italy
- #530 of 618
- Research works
- 236 ▲ 26% vs 2013–17
- Citations
- 4.3k 18.2 per fractional work
- Top-10% rate
- 20.2% record average 16.5%
- Open access
- 56% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Economics, Econometrics and Finance, 8.8×. Every wedge is a field page.
- Economics, Econometrics and Finance 8.8×
- Pharmacology, Toxicology and Pharmaceutics 6.3×
- Immunology and Microbiology 3.2×
- Health Professions 2.4×
- Medicine 1.9×
- Mathematics 1.2×
- Social Sciences 0.9×
- Environmental Science 0.8×
- Biochemistry, Genetics and Molecular Biology 0.8×
- Business, Management and Accounting 0.7×
- Arts and Humanities 0.7×
- Earth and Planetary Sciences 0.6×
- Energy 0.5×
- Chemical Engineering 0.3×
- Veterinary 0.3×
- Computer Science 0.3×
- Neuroscience 0.2×
- Psychology 0.2×
- Physics and Astronomy 0.2×
- Nursing 0.2×
- Engineering 0.2×
- Chemistry 0.1×
- Agricultural and Biological Sciences 0.1×
- Decision Sciences 0.1×
- Materials Science 0.0×
Who are the top researchers at Italian Medicines Agency?
Ranked on the composite score, Francesco Trotta, Federica Cuppone and Pierluigi Russo lead among researchers whose main affiliation is Italian Medicines Agency.
- 1 Francesco Trotta Italy · #961,862 worldwide 85 citations · 167 works
- 2 Federica Cuppone Italy · #1,414,710 worldwide 15 citations · 21 works
- 3 Pierluigi Russo Italy · #1,542,164 worldwide 3 citations · 24 works
Which keywords describe research at Italian Medicines Agency?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Economic Evaluation, Quality of Life, Clinical Trials, Pharmaceutical Industry, Cost-effectiveness Analysis, Health Utility Measures, Drug Development Costs and Generic Drugs.
- Polypharmacy
- Global Governance
- Regenerative Medicine
- Cross-Border Regions
- Regulatory Challenges
- Health Care Expenditure
- Ageing Population
- Monoclonal Antibodies
- ACE2 Receptor
- Infectious Diseases
- Primary Care
- Health Outcomes
- Pediatric Pharmacokinetics
- Drug Development
- Public Health
- Adverse Drug Reactions
- Health Utility Measures
- Drug Development Costs
- Pharmaceutical Industry
- Economic Evaluation
- Quality of Life
- Clinical Trials
- Cost-effectiveness Analysis
- Generic Drugs
- Epidemiology
- Medication Adherence
- Economic Growth
- Off-Label Drug Use
- Pandemic
- Patient Safety
- Cultural Heritage
- Health Equity
- Chronic Disease
- SARS-CoV-2
- Gender Inequality
- Public-Private Partnerships
- Clinical Outcomes
- Mutation
- Territorial Governance
- Inappropriate Medication Use
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Quality of Life7▲ 6.5×6 topics
- Economic Evaluation6▲ 71×2 topics
- Clinical Trials6▲ 12×10 topics
- Pharmaceutical Industry6▲ 215×2 topics
- Cost-effectiveness Analysis6▲ 89×1 topic
- Drug Development Costs6▲ 285×1 topic
- Generic Drugs6▲ 285×1 topic
- Health Utility Measures6▲ 89×1 topic
- Epidemiology5▲ 1.88×23 topics
- Adverse Drug Reactions4▲ 95×2 topics
- Medication Adherence3▲ 82×2 topics
- Public Health3▲ 3.0×11 topics
- Economic Growth3▲ 4.9×7 topics
- Drug Development3▲ 45×3 topics
- Off-Label Drug Use3▲ 140×1 topic
- Pediatric Pharmacokinetics3▲ 140×1 topic
- Pandemic2▲ 2.8×6 topics
- Health Outcomes2▲ 10×4 topics
- Patient Safety2▲ 19×3 topics
- Primary Care2▲ 7.3×6 topics
- Cultural Heritage2▲ 4.7×5 topics
- Infectious Diseases2▲ 7.7×4 topics
- Health Equity2▲ 8.0×4 topics
- ACE2 Receptor2▲ 8.7×2 topics
- Chronic Disease2▲ 12×2 topics
- Monoclonal Antibodies2▲ 23×3 topics
- SARS-CoV-22▲ 6.5×2 topics
- Ageing Population1▲ 48×1 topic
- Gender Inequality1▲ 14×2 topics
- Health Care Expenditure1▲ 48×1 topic
- Public-Private Partnerships1▲ 26×2 topics
- Regulatory Challenges1▲ 22×2 topics
- Clinical Outcomes1▲ 8.1×3 topics
- Cross-Border Regions1▲ 238×1 topic
- Mutation1▲ 9.4×4 topics
- Regenerative Medicine1▲ 7.2×2 topics
- Territorial Governance1▲ 14×1 topic
- Global Governance1▲ 7.4×2 topics
- Inappropriate Medication Use1▲ 38×1 topic
- Polypharmacy1▲ 38×1 topic
Which research topics does Italian Medicines Agency publish most on?
By volume in 2022–2025: Health Systems, Economic Evaluations, Quality of Life, Pharmaceutical Economics and Policy, Pharmaceutical studies and practices and Global Health Care Issues.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 6 works
- 2 Pharmaceutical Economics and Policy Economics and Econometrics 6 works
- 3 Pharmaceutical studies and practices Pediatrics, Perinatology and Child Health 3 works
- 4 Global Health Care Issues General Health Professions 1 works
- 5 Cross-Border Cooperation and Integration Political Science and International Relations 1 works
- 6 Pharmaceutical Practices and Patient Outcomes Geriatrics and Gerontology 1 works
- 7 Biomedical Ethics and Regulation Physiology 1 works
- 8 Biosimilars and Bioanalytical Methods Immunology 1 works
- 9 Poverty, Education, and Child Welfare Safety Research 1 works
- 10 Bayesian Modeling and Causal Inference Artificial Intelligence 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Italian Medicines Agency's research output changed?
Output in 2018–2022 was 26% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Rome
- Sapienza University of Rome
- University of Rome Tor Vergata
- Istituti di Ricovero e Cura a Carattere Scientifico
- National Research Council
- Roma Tre University
- Istituto Superiore di Sanità
- National Agency for New Technologies, Energy and Sustainable Economic Development
- Agostino Gemelli University Polyclinic
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.